People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TORL Biotherapeutics LLC | — | Pharmaceuticals | Series D+ | $158.3M | $1.8B | 2024 |
Lynn Seely at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lynn Seely on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Licata | 1 | 4 |
| Mark Attanasio | 1 | 3 |
| Neil ` O'Brien | 1 | 3 |
| Mark Alles | 1 | 3 |
| Dennis Slamon | 1 | 2 |
| Amit Sinha | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.